Pemetrexed has now been recommended for the first-line treatment of non-small-cell lung cancer (see NICE technology appraisal guidance 181). NICE technology appraisal guidance 124 applies to patients who have had prior chemotherapy.
- Pemetrexed is not recommended for the treatment of locally advanced or metastatic non-small-cell lung cancer.
- People currently receiving pemetrexed should have the option to continue therapy until they and their clinicians consider it appropriate to stop.
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.